Eli Lilly and Company $LLY Shares Sold by Waterway Wealth Management LLC

Waterway Wealth Management LLC lowered its position in Eli Lilly and Company (NYSE:LLY) by 41.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,008 shares of the company’s stock after selling 722 shares during the quarter. Waterway Wealth Management LLC’s holdings in Eli Lilly and Company were worth $1,083,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in LLY. Brighton Jones LLC lifted its stake in shares of Eli Lilly and Company by 22.0% during the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after purchasing an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC lifted its stake in shares of Eli Lilly and Company by 2.8% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after purchasing an additional 40 shares in the last quarter. Schnieders Capital Management LLC. lifted its stake in shares of Eli Lilly and Company by 16.7% during the second quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company’s stock worth $6,231,000 after purchasing an additional 1,141 shares in the last quarter. Flow Traders U.S. LLC acquired a new position in shares of Eli Lilly and Company during the second quarter worth about $356,000. Finally, Nebula Research & Development LLC acquired a new position in shares of Eli Lilly and Company during the second quarter worth about $749,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 0.6%

NYSE:LLY opened at $1,122.47 on Wednesday. The firm has a market capitalization of $1.06 trillion, a PE ratio of 39.87, a price-to-earnings-growth ratio of 1.23 and a beta of 0.53. The stock has a 50 day moving average of $1,006.08 and a 200-day moving average of $1,016.63. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,182.73. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating the consensus estimate of $6.97 by $1.58. The company had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The business’s revenue was up 55.5% compared to the same quarter last year. During the same period in the prior year, the company earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Analysts predict that Eli Lilly and Company will post 35.8 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th were issued a dividend of $1.73 per share. The ex-dividend date of this dividend was Friday, May 15th. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is 24.58%.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Eli Lilly announced it is acquiring 4E Therapeutics, a developer of non-opioid pain treatments, expanding beyond obesity and diabetes into the large painkiller market. Investors may view the deal as a strategic move to diversify Lilly’s pipeline and create another long-term growth driver. Lilly buys non-opioid pain drugmaker 4E
• Positive Sentiment: The company also advanced several early-stage programs, including an oral candidate, an Alzheimer’s drug, and other clinical trial updates, which suggests Lilly continues to deepen its pipeline beyond its blockbuster GLP-1 franchise. Eli Lilly Advances New Oral Candidate With Fresh Phase 1 Bioavailability Study
• Positive Sentiment: Broader sector and market commentary remains constructive for GLP-1 leaders like Lilly, with reports projecting strong long-term growth in the global GLP-1 receptor agonist market. Global GLP-1 Receptor Agonist Market Size/Share Worth USD 95.3 Billion by 2035
• Neutral Sentiment: Healthcare stocks were broadly firmer in afternoon trading, which may be providing a small tailwind for Lilly alongside the company-specific news. Sector Update: Healthcare Stocks Advance in Afternoon Trading
• Negative Sentiment: Some headlines point to competitive pressure from Novo Nordisk and concerns that Lilly’s GLP-1 drugs could face new reimbursement or demand headwinds, which could temper enthusiasm if those risks grow. Eli Lilly’s hottest drugs face a quiet new threat

Analyst Ratings Changes

A number of research analysts have commented on the company. Berenberg Bank boosted their price objective on Eli Lilly and Company from $950.00 to $1,050.00 and gave the stock a “hold” rating in a research note on Thursday, February 19th. Jefferies Financial Group boosted their price objective on Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the company a “buy” rating in a report on Tuesday, June 9th. Daiwa Securities Group boosted their price objective on Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the company a “buy” rating in a report on Wednesday, February 18th. Bank of America boosted their price objective on Eli Lilly and Company from $1,133.00 to $1,251.00 and gave the company a “buy” rating in a report on Tuesday, May 26th. Finally, HSBC lowered Eli Lilly and Company from a “hold” rating to a “reduce” rating and lowered their price objective for the company from $1,070.00 to $850.00 in a report on Tuesday, March 17th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,227.74.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.